CTLA4 and pancreatic neoplasm: A study in the Pan02 model of mouse pancreatic cancer revealed that the combination of agnostic anti-OX40 and inhibitory anti-CTLA4 led to transient decrease in ARG1 expression in TAMs, giving a therapeutic window for gemcitabine (346).